Published in Hum Pathol on April 06, 2013
A quantitative histomorphometric classifier (QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2014) 0.95
Cyclin D1 overexpression is associated with poor clinicopathological outcome and survival in oral squamous cell carcinoma in Asian populations: insights from a meta-analysis. PLoS One (2014) 0.83
Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma. Mol Clin Oncol (2014) 0.80
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncol (2016) 0.75
Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol (2016) 0.75
The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2014) 0.75
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol (2001) 4.83
RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn (2012) 4.63
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene (2006) 2.56
Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck (2011) 2.30
HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol (2009) 2.08
High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2011) 2.00
The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck (2004) 1.42
p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.38
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res (2006) 1.37
An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer (2012) 1.36
Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer (1997) 1.34
P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol (2009) 1.29
Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med (2011) 1.28
Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. Mod Pathol (2012) 1.23
Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg (1995) 1.15
A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer (2012) 1.11
Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res (2005) 1.08
Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer. Int J Cancer (2010) 1.04
Equivocal p16 immunostaining in squamous cell carcinoma of the head and neck: staining patterns are suggestive of HPV status. Head Neck Pathol (2012) 1.04
p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1. PLoS One (2011) 1.02
Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer (1997) 0.93
Human papillomavirus, p53 and cyclin D1 expression in oropharyngeal carcinoma. Int J Oral Maxillofac Surg (2003) 0.92
Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers. Am J Surg Pathol (2012) 0.86
Molecular markers in head and neck squamous cell carcinoma: their biological function and prognostic significance. Ann Otol Rhinol Laryngol (2001) 0.83
p16, Cyclin D1, and HIF-1α Predict Outcomes of Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Definitive Intensity-Modulated Radiation Therapy. Int J Otolaryngol (2012) 0.81
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol (2009) 3.38
p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol (2010) 3.37
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med (2008) 2.68
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis (2012) 2.58
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck (2011) 2.30
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother (2012) 2.17
MR imaging of the spleen: spectrum of abnormalities. Radiographics (2005) 2.16
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol (2009) 2.08
Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother (2005) 2.05
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Hum Pathol (2010) 2.01
High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2011) 2.00
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy (2003) 1.85
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77
Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother (2005) 1.69
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother (2008) 1.67
Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys (2004) 1.64
Adenosquamous carcinoma of the head and neck: relationship to human papillomavirus and review of the literature. Head Neck Pathol (2011) 1.61
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
A retrospective comparison of 2 methods of intraoperative margin evaluation during partial nephrectomy. J Urol (2008) 1.49
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol (2010) 1.45
18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med (2011) 1.45
Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope (2010) 1.42
Adrenal masses: mr imaging features with pathologic correlation. Radiographics (2004) 1.38
Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope (2009) 1.37
Predicting dose-volume histograms for organs-at-risk in IMRT planning. Med Phys (2012) 1.35
ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34
Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol (2005) 1.33
IMRT treatment planning based on prioritizing prescription goals. Phys Med Biol (2007) 1.32
Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother (2012) 1.31
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat (2009) 1.28
Transcriptionally-active high-risk human papillomavirus is rare in oral cavity and laryngeal/hypopharyngeal squamous cell carcinomas--a tissue microarray study utilizing E6/E7 mRNA in situ hybridization. Histopathology (2012) 1.25
Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin Proc (2010) 1.24
Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. Mod Pathol (2012) 1.23
Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res (2012) 1.23
Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.22
Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med (2014) 1.21
Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus. Am J Surg Pathol (2013) 1.18
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res (2009) 1.16
MRI of adrenal and extraadrenal pheochromocytoma. AJR Am J Roentgenol (2005) 1.16
A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer (2012) 1.11
Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol (2008) 1.11
Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy (2011) 1.10
CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res (2011) 1.09
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun (2008) 1.09
Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer (2011) 1.09
Human papillomavirus-related squamous cell carcinoma of the oropharynx: a comparative study in whites and African Americans. Arch Otolaryngol Head Neck Surg (2011) 1.07
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother (2012) 1.07
Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA. Mod Pathol (2003) 1.06
B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.05
Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol (2009) 1.05
Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med (2010) 1.05
Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. Mod Pathol (2011) 1.04
Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma - a prospective cohort and interobserver variability study. Histopathology (2011) 1.03
Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis (2005) 1.03
Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer (2009) 1.03
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther (2013) 1.02
A novel PET tumor delineation method based on adaptive region-growing and dual-front active contours. Med Phys (2008) 1.02
Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm (2011) 1.01
Ameloblastic carcinosarcoma of the mandible arising in ameloblastic fibroma: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 1.01
Role of fusion in radiotherapy treatment planning. Semin Nucl Med (2003) 1.00
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2009) 0.98
Detection and significance of human papillomavirus, CDKN2A(p16) and CDKN1A(p21) expression in squamous cell carcinoma of the larynx. Mod Pathol (2012) 0.98
Extracapsular extension is a poor predictor of disease recurrence in surgically treated oropharyngeal squamous cell carcinoma. Mod Pathol (2011) 0.98
Large cell neuroendocrine carcinoma of the larynx: definition of an entity. Head Neck Pathol (2010) 0.96
Evaluation of a new grading system for laryngeal squamous intraepithelial lesions--a proposed unified classification. Histopathology (2014) 0.96
Merkel cell carcinoma of the head and neck. Head Neck (2011) 0.96
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res (2011) 0.95
The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother (2007) 0.95